The cost-effectiveness of bendamustine-rituximab (BEN-R) versus R-CHOP for the first line treatment of patients with indolent non-Hodgkin’s lymphoma (INHL) in Colombia

Abstract:

Objectives To determine the cost-effectiveness of Ben-R versus R-CHOP for the first-line treatment of patients with iNHL in Colombia. Methods An economic model was constructed from the Colombian public payer perspective, with a lifetime horizon and discount rate of 5%. The model included three health states: progression-free (PF), progressive disease (PD) and death. Clinical inputs and PFS information were based on phase 3 clinical data. Overall survival (OS) data was not mature at the time of publication and the model conservatively assumes non-differential survival, estimated by disease-related mortality adjustments applied to all-cause mortality rates in Colombia. Therefore, the analysis focused on progression-free life year (PFLY) outcomes as the most relevant measure of incremental treatment effect. Treatment patterns for 1st and 2ndline chemotherapy and resource use for disease monitoring and …

Año de publicación:

2015

Keywords:

Fuente:

google